Sponsored by
The Bottom Line Upfront 💡
Merck $MRK ( ▲ 2.48% ) is a world-class oncology franchise fairly valued at ~$124 — but half its revenue rides on one drug facing a 2028 patent cliff. The next three years are a race between Keytruda’s expiration and a pipeline that must replace it. Own it if you believe the science delivers.
Sponsorship
Stop overpaying for wireless. Get a Tello plan for under $25
Unlimited everything. No contract. Just $25/mo. With Tello, you get reliable 5G coverage, zero hidden fees, and none of the bundles you never wanted.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Merck is a global pharmaceutical giant that does one thing exceptionally well: turn cutting-edge science into drugs people desperately need, then charge accordingly. With ~75,000 employees and $65B in annual revenue, it’s one of the biggest players in healthcare.
Two segments, one mission:
🔬 Pharmaceutical ($58.1B, 89% of revenue): Prescription drugs and vaccines sold to hospitals, wholesalers, pharmacies, and government programs. The crown jewel is Keytruda (pembrolizumab), a cancer immunotherapy approved in 40+ indications across 19 tumor types. At $31.7B in 2025 sales, it’s the best-selling drug on the planet. Full stop.
🐮 Animal Health ($6.4B, 10% of revenue): Vaccines, antibiotics, and parasite treatments for livestock and pets. Bravecto (flea/tick prevention) is the star companion animal product. This segment is the quiet overachiever — up 8% in 2025 ↗️.
How they make money: Patent-protected drugs sold at premium prices. Merck invests heavily in R&D (~$15.8B in 2025), gets FDA approval, then enjoys years of exclusivity before generics crash the party. They also earn alliance revenue from partnerships with AstraZeneca (Lynparza), Eisai (Lenvima), and Bristol Myers Squibb (Reblozyl).
Key internal metrics: Keytruda sales growth, pipeline Phase 3 trial count (~80 active), new regulatory approvals (25 in 2025 alone), and segment profit margins.
Key Takeaway: Merck is essentially a Keytruda delivery vehicle with a solid supporting cast — and that’s both its greatest strength and its biggest vulnerability.
Layer 2: Category Position 🏆
Merck competes against the who’s-who of Big Pharma: Pfizer, Eli Lilly, AstraZeneca, Roche, and others. In oncology, it’s a heavyweight — Keytruda dominates the checkpoint inhibitor market, though Bristol Myers Squibb’s Opdivo is a persistent rival.
Where Merck wins:
Keytruda’s breadth of approvals is unmatched — competitors can’t replicate 40+ indications overnight
Animal Health is a consistent grower in a less-competitive niche
Winrevair (pulmonary arterial hypertension) is a new franchise with blockbuster potential — $1.4B in just its second year ↗️
Where Merck is getting bruised:
Gardasil collapsed — down 39% to $5.2B in 2025, almost entirely due to China ↘️. The company literally stopped shipping there mid-year due to bloated distributor inventory. Ouch.
Januvia/Janumet face generic entry in mid-2026. The diabetes franchise is essentially in hospice care.
Bridion loses U.S. exclusivity in July 2026. Another one bites the dust.
A biosimilar of Keytruda has already launched in Argentina — a small market, but a preview of what’s coming globally post-2028.
Key Takeaway: Merck is the undisputed oncology king today, but the throne gets contested in 2028 when Keytruda’s patent expires.
Layer 3: Show Me The Money! 📈
Revenue breakdown:
U.S.: $36.5B (56%), +13% — the domestic engine is firing ↗️
International: $28.5B (44%), -11% — Gardasil’s China collapse dragged this down hard ↘️
The Keytruda math is staggering: One drug = 49% of total company revenue. That’s either impressive or terrifying depending on your risk tolerance. (Spoiler: it’s both.)
Winners in 2025:
Keytruda/Keytruda Qlex: $31.7B, +7% ↗️
Winrevair: $1.4B, +244% (launched 2024) ↗️
Welireg: $716M, +41% ↗️
Animal Health: $6.4B, +8% ↗️
Capvaxive: $759M (essentially new) ↗️
Losers in 2025:
Gardasil: $5.2B, -39% ↘️
Lagevrio (COVID pill): $380M, -61% ↘️
Dificid: $247M, -27% (lost exclusivity July 2025) ↘️
Margins: Gross margin dipped to 74.8% from 76.3%, partly due to restructuring charges and acquisition-related inventory step-ups ↘️. Non-GAAP EPS of $8.98 grew 17% — the underlying business is healthy ↗️.
Cash flow reality check: Operating cash flow fell to $16.5B from $21.5B in 2024, driven by higher taxes ($6.1B paid) and acquisition payments ↘️. Merck returned $13.3B to shareholders (dividends + buybacks) — more than its FCF of ~$12.4B. They funded the gap with debt, which jumped 33% to $49.3B ↗️. Worth watching.
Key Takeaway: The financial engine is strong, but Merck is spending aggressively on acquisitions and returning more cash than it generates — a bet that the pipeline pays off.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Fairly Valued — with meaningful downside risk if the Keytruda cliff hits harder than expected.
Scenario | Fair Value | vs. Current Price (~$127) |
|---|---|---|
Conservative | $72.74 | -41% ↘️ |
Base Case | $122.50 | ~Flat |
Optimistic | $160.07 | +29% ↗️ |
Key assumptions driving the range:
The Keytruda cliff is real: Patent expiry in 2028 could erase $10-15B in annual revenue by 2031 as biosimilars enter
Pipeline must deliver: Winrevair, Ohtuvayre, and a dozen oncology ADCs need to collectively replace Keytruda’s contribution
WACC matters enormously: At 6.4% (optimistic), you get $160; at 7.5% (conservative), you get $73 — that’s the sensitivity of a long-duration asset like pharma
One-line take: At ~$124, you’re paying for a company that executes its pipeline perfectly — any stumbles and the downside is steep.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
Winrevair becomes a $5B+ blockbuster — PAH is a large, underserved market and early data is compelling
Keytruda Qlex (subcutaneous) extends the franchise — the new formulation could maintain market share even after IV biosimilars arrive
The ADC pipeline delivers — Merck has 5+ antibody-drug conjugates in Phase 3 with Daiichi Sankyo; even 2-3 approvals could be transformative
Bear Case 🐻
Keytruda biosimilar penetration is faster than expected — if 40% of revenue evaporates by 2031 and the pipeline isn’t ready, this stock has serious downside
Acquisition integration disappoints — Merck spent ~$20B on Verona Pharma and Cidara in 12 months; that’s a lot of eggs in new baskets
Drug pricing pressure intensifies — IRA negotiations, MFN pricing agreements, and Medicaid rebate dynamics are structural headwinds that don’t go away
The Bottom Line: Merck is a high-quality business at a fair price — not a screaming bargain, not obviously overvalued. The next 3 years are a race between patent expirations and pipeline execution. If you believe in the science, the dividend (~2.7%, growing) pays you to wait. If you’re skeptical, the conservative DCF suggests real downside. This is a “know what you own” stock if there ever was one.
Layer 6: What to Watch 👀
Keytruda growth rate — If it dips below 5% annually before 2028, the market will start pricing in the cliff aggressively. Watch quarterly sales closely.
Winrevair trajectory — The ZENITH trial expanded the label; peak sales estimates range from $5-8B. Quarterly uptake data will tell you if this is the next blockbuster or a niche product.
China Gardasil recovery — Merck stopped all shipments in 2025. Any resumption signals demand normalization; continued silence signals structural market loss.
Pipeline readouts — PDUFA dates to watch: Welireg + Keytruda for kidney cancer (June 2026), Welireg + Lenvima for RCC (October 2026), and Keytruda + Trodelvy for triple-negative breast cancer (H2 2026).
Debt levels — Long-term debt jumped to $46.8B ↗️. Watch the debt-to-equity ratio; if acquisitions continue without FCF improvement, the balance sheet gets uncomfortable fast.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.